New engineered cell therapy tested in kids with Tough-to-Treat cancers

This study tested a new type of personalized cell therapy for children and young adults whose leukemia or lymphoma had come back or did not respond to standard treatments. Researchers collected a patient's own immune cells, genetically modified them in a lab to recognize a protein called CD22 on cancer cells, and then infused them back into the patient. The main goals were to see if this approach was safe and to find the right dose, while also checking for early signs that it could help control the cancer.